Donitriptan ( INN) (code name F-11356) is a triptan drug which was investigated as an antimigraine agent but ultimately was never marketed. It acts as a high-  affinity, high- efficacy/near- full agonist of the 5-HT (pK 1B i = 9.4–10.1; IA = 94%) and 5-HT (pK 1D receptors i = 9.3–10.2; IA = 97%), and is among the most potent of the triptan series of drugs.   Donitriptan was being developed in  France by bioMérieux- Pierre Fabre and made it to phase II clinical trials in Europe before development was discontinued.  
References [ edit ]
Dukat M (March 2001). "Donitriptan (Pierre Fabre)". Curr Opin Investig Drugs. 2 (3): 415–8. PMID 11575714.
^ Perez M, Fourrier C, Sigogneau I, Pauwels PJ, Palmier C, Valentin JP, John GW, Halazy S (1995) Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: Potent agonists for 5-HT1D receptors.
Journal of Medicinal Chemistry 38:3602–3607.
Jes Olesen (2006). . Lippincott Williams & Wilkins. pp. 470–. The Headaches ISBN 978-0-7817-5400-2.
John GW, Pauwels PJ, Perez M, et al. (July 1999). "F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine". J. Pharmacol. Exp. Ther. 290 (1): 83–95. PMID 10381763.
Chas Bountra; Rajesh Munglani; William K. Schmidt (28 May 2013). . CRC Press. pp. 402–. Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery ISBN 978-0-203-91125-9.
W.W. Fleischhacker; D.J. Brooks (21 May 2003). . Springer Vienna. pp. 38–. Neuropsychopharmacology ISBN 978-3-211-83903-4.
Stewart J. Tepper (2004). . Univ. Press of Mississippi. pp. 118–. Understanding Migraine and Other Headaches ISBN 978-1-60473-048-7.